European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast CancerPRNewsWire • 07/09/24
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbesPRNewsWire • 07/01/24
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024PRNewsWire • 06/18/24
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal FunctionPRNewsWire • 06/12/24
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 06/04/24
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness PlanPRNewsWire • 06/04/24
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024PRNewsWire • 05/28/24
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024PRNewsWire • 05/21/24
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company ShowcasePRNewsWire • 05/20/24
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published GloballyPRNewsWire • 05/07/24
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast CancerPRNewsWire • 04/15/24
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing ClearancePRNewsWire • 04/03/24
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with CryoprobesPRNewsWire • 04/02/24
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024PRNewsWire • 03/27/24
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to LumpectomyPRNewsWire • 03/19/24
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient OutcomesPRNewsWire • 03/12/24
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services ConferencePRNewsWire • 03/07/24
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024PRNewsWire • 03/04/24
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions WorkshopPRNewsWire • 02/27/24
Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast CancerPRNewsWire • 02/26/24
